Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors

Conditions:   TNBC - Triple-Negative Breast Cancer;   Head and Neck Squamous Cell Carcinoma;   Squamous Cell Carcinoma of Anal Canal;   Uveal Melanoma;   Glioblastoma;   Colorectal Cancer;   Chordoma;   Squamous Cell Carcinoma of the Lung;   KRAS G12D;   KRAS G13D;   EGFR Amp lification;   Epithelial Ovarian Cancer;   Hepatocellular Carcinoma;   Anaplastic Thyroid Cancer;   Pancreas Cancer Interventions:   Drug: BCA101;   Drug: Pembrolizumab Sponsor:   Bicara Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials